{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:18:30Z","timestamp":1787314710802,"version":"build-2736575974"},"reference-count":27,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"\n Purpose<\/jats:title>\n We aimed to investigate the role of skin tests (ST) in the diagnosis of hypersensitivity reactions (HSRs) with platinum salts (PS) and taxane (TX) groups drugs and their reliability in patient management.<\/jats:p>\n <\/jats:sec>\n \n Materials and Method<\/jats:title>\n Patients' data who developed immediate HSR with PS and TX were recorded and ST was performed. The gradual challenge was applied to all patients with ST negative and grade 1\u20132 with the suspect drug.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In total, the data of 104 patients (74 with PS, 30 with TX) who developed HSR against PS and TX were shared. The gradual challenge was applied to 72 ST negative and grade 1\u20132 patients (46 PS group, 26 TX group). The gradual challenge was negative in 39 patients in the PS group and 23 patients in the Tx group. The negative predictive value (NPV) for PS was 83% and NPV for TX was 88%. We found significantly higher skin test positivity in patients with PS and TX and grade 3 HSR (\n p<\/jats:italic>\n \u2009=\u20090.007,\n p<\/jats:italic>\n \u2009=\u20090.001). A significant correlation was found between skin test positivity and early onset of symptoms (\n p<\/jats:italic>\n \u2009=\u20090.001 for PS,\n p<\/jats:italic>\n \u2009=\u20090.015 for TX). In terms of symptoms witnessed in HSR, we observed the itching, urticaria, hypotension, syncope, and abdominal pain symptoms significantly more in the group with a positive skin test (\n p<\/jats:italic>\n \u2009<\u20090.024,\n p<\/jats:italic>\n \u2009<\u20090.001,\n p<\/jats:italic>\n \u2009<\u20090.001,\n p<\/jats:italic>\n \u2009<\u20090.002, and\n p<\/jats:italic>\n \u2009<\u20090.025, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n We found very high NPV values for PS and TX. We found that the gradual challenge applied to patients with negative skin tests is reliable if Grade 3 HSR is not observed and with this approach, unnecessary desensitization processes and\/or drug alterations can be avoided.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552211050084","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T14:07:01Z","timestamp":1638281221000},"page":"1111-1119","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis?"],"prefix":"10.1177","volume":"28","author":[{"given":"Kadriye","family":"Terzio\u011flu","sequence":"first","affiliation":[{"name":"Health Science University Kartal Dr L\u00fctfi Kirdar City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-4006","authenticated-orcid":false,"given":"Murat","family":"Ayhan","sequence":"additional","affiliation":[{"name":"Health Science University Kartal Dr L\u00fctfi Kirdar City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"253","article-title":"Hypersensitivity reactions to chemotherapeutic drugs","volume":"24","author":"Shepherd GM","year":"2003","unstructured":"Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. ClinRevAllergyImmunol 2003; 24: 253\u2013262.","journal-title":"ClinRevAllergyImmunol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/207084"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx216"},{"key":"e_1_3_2_5_2","first-page":"177","article-title":"Re-visiting hypersensitivity reactions to taxanes: a comprehensive review","volume":"49","author":"Picard M","year":"2015","unstructured":"Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. ClinRevAllergyImmunol 2015; 49: 177\u2013191.","journal-title":"ClinRevAllergyImmunol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1263"},{"key":"e_1_3_2_7_2","first-page":"375","article-title":"Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies","volume":"54","author":"Bonamichi-Santos R","year":"2018","unstructured":"Bonamichi-Santos R, Castells MC. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. ClinRevAllergy Immunol 2018; 54: 375\u2013385.","journal-title":"ClinRevAllergy Immunol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12350"},{"key":"e_1_3_2_9_2","first-page":"1","volume-title":"1. Bask\u0131","author":"\u00c7elik GE","year":"2014","unstructured":"\u00c7elik GE. \u0130la\u00e7 a\u015f\u0131r\u0131 duyarl\u0131l\u0131k reaksiyonlar\u0131na yakla\u015f\u0131m ulusal rehber. 1. Bask\u0131. Ankara: Bilimsel T\u0131p Yay\u0131nevi 2014, pp.1\u20136."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.539"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg092"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.09.018"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124100-00005"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12142"},{"key":"e_1_3_2_15_2","first-page":"371","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown SG","year":"2004","unstructured":"Brown SG. Clinical features and severity grading of anaphylaxis. J AllergyClinImmunol 2004; 114: 371\u2013376.","journal-title":"J AllergyClinImmunol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.12.032"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.08.011"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.07.003"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.10.037"},{"key":"e_1_3_2_20_2","first-page":"428","article-title":"Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review","volume":"2","author":"Banerji A","year":"2014","unstructured":"Banerji A, Lax T, Guyer A, et al. Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J AllergyClinImmunolPract 2014; 2: 428\u2013433.","journal-title":"J AllergyClinImmunolPract"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0515-3"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.01.008"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061316"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601155"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11379"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055363"},{"key":"e_1_3_2_27_2","first-page":"1671","article-title":"Hypersensitivity reactions to oxaliplatin: incidence and management","volume":"18","author":"Gowda A","year":"2004","unstructured":"Gowda A, Goel R, Berdzik J, et al. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology 2004; 18: 1671\u20131675.","journal-title":"Oncology"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1141"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211050084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211050084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211050084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:49Z","timestamp":1779194269000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211050084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552211050084"],"URL":"https:\/\/doi.org\/10.1177\/10781552211050084","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}